CLAIMS

1. A compound represented by Formula (1):

[Formula 1]



(I)

wherein Cy is an aromatic hydrocarbon group which may be substituted, or an aromatic heterocyclic group which may be substituted; R^1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is -C(O)-, -S(O)-, or $-S(O)_2-$; W is $-N(R^2)-$, -O-, or a bond (wherein R^2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is alkylene which may be substituted; Y is -C(O)-, -S(O)-, or $-S(O)_2-$; Z is a bond, a chain hydrocarbon group which may be substituted, or -N=; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; and ring B is a nitrogen-containing heterocyclic group which may be substituted;



is each independently a single bond or a double bond; R^1 and R^2 may be bonded to each other to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; and R^2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted,

or a salt thereof.

2. A prodrug of the compound according to claim 1.

3. The compound according to claim 1, wherein Cy is phenyl which may be substituted, or a 5- to 6-membered aromatic monocyclic heterocyclic group which may be substituted.

4. The compound according to claim 1, wherein Cy is phenyl which may be substituted with a halogen atom.

5. The compound according to claim 1, wherein R^1 is a hydrogen atom.

6. The compound according to claim 1, wherein V is -C(O)-.

7. The compound according to claim 1, wherein W is -$N(R^2)$-.

8. The compound according to claim 1, wherein X is C_{1-4} alkylene which may be substituted with a hydrocarbon group which may be substituted, an aromatic heterocyclic group which may be substituted, a hydroxyl group which may be substituted, amino which may be substituted, carbamoyl which may be substituted or carboxyl which may be

esterified.

9. The compound according to claim 1, wherein X is methylene which may be substituted with a hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted.

10. The compound according to claim 1, wherein Y is -C(O)-.

11. The compound according to claim 1, wherein -W-X-Y- is an amino acid residue.

12. The compound according to claim 1, wherein ring A is a piperidine ring which may be substituted, or a piperazine ring which may be substituted.

13. The compound according to claim 1, wherein ring B is a monocyclic nitrogen-containing heterocyclic ring which may be substituted.

14. The compound according to claim 13, wherein the monocyclic nitrogen-containing heterocyclic ring is a piperidine ring, a piperazine ring, a morpholine ring, an imidazoline ring, a pyrrolidine ring, a pyridine ring, an imidazole ring, or a thiazoline ring.

15. The compound according to claim 1, wherein ring B is a fused nitrogen-containing heterocyclic ring which may be substituted.

16. The compound according to claim 15, wherein the fused nitrogen-containing heterocyclic ring is a fused pyridine ring, a fused imidazole ring, a fused pyrazole ring, or a fused thiazoline ring.

17. The compound according to claim 1, wherein Z is a bond or C_{1-6} alkylene.

18. A compound selected from the group consisting of N-(4-chlorophenyl)-N'-((1R)-2,2-dimethyl-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)propyl)urea, N-(4-chlorophenyl)-N'-(2-ethyl-2-hydroxy-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)butyl)urea, N-(4-chlorophenyl)-N'-((1S)-2-methyl-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)-2-(methylthio)propyl)urea, and N-(4-chlorophenyl)-N'-(2-methoxy-2-methyl-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)propyl)urea, or a salt thereof.

19. A pharmaceutical composition comprising the compound according to claim 1 or 2.

20. The pharmaceutical composition according to claim 19, which is an anticoagulant.

21. The pharmaceutical composition according to claim 19, which is an activated blood coagulation factor X inhibitor.

22. The pharmaceutical composition according to claim 19, which is a prophylactic and/or therapeutic agent for myocardial infarction, cerebral infarction, deep vein thrombosis, pulmonary thromboembolism, or arteriosclerosis obliterans.

23. The pharmaceutical composition according to claim 19, which is a prophylactic and/or therapeutic agent for economy-class syndrome, thromboembolism during and post operation, or the secondary onset of deep vein thrombosis.

24. A method of inhibiting blood coagulation in mammal which comprises administering an effective amount of the compound according to claim 1 or a prodrug thereof to the mammal.

25. A method of inhibiting activated blood coagulation

factor X in mammal which comprises administering an effective amount of the compound according to claim 1 or a prodrug thereof to the mammal.

26. A method of preventing and/or treating myocardial infarction, cerebral infarction, deep vein thrombosis, pulmonary thromboembolism or arteriosclerosis obliterans in mammal which comprises administering an effective amount of the compound according to claim 1 or a prodrug thereof to the mammal.

27. Use of the compound according to claim 1 or a prodrug thereof, for the manufacture of a medicine for inhibiting blood coagulation.

28. Use of the compound according to claim 1 or a prodrug thereof, for the manufacture of a medicine for inhibiting activated blood coagulation factor X.

29. Use of the compound according to claim 1 or a prodrug thereof, for the manufacture of a medicine for preventing and/or treating myocardial infarction, cerebral infarction, deep vein thrombosis, pulmonary thromboembolism, or arteriosclerosis obliterans.